A phase 2 study evaluated the use of ruxolitinib plus standard GVHD prophylaxis in patients with myelofibrosis undergoing ...

The addition of itacitinib to standard graft-versus-host-disease prophylaxis may reduce severe toxicities following ...

Fred Hutch’s Phase 2 study among blood cancer patients is a “gamechanger” in preventing graft-versus-host disease after ...

Post-transplant cyclophosphamide (PTCy) plus sirolimus and cyclosporine can improve some outcomes when compared to mycophenolate mofetil (MMF) plus sirolimus and cyclosporine as graft-vs-host disease ...

Chronic GvHD can be difficult to cope with. It can affect your quality of life. Find out more about how it might affect you and what support is available. The length of time you have chronic GvHD can ...

The regulator has cleared Ryoncil (remestemcel-L) to treat steroid-refractory acute GVHD in paediatric patients aged two months and older. It is derived from MSCs harvested from the bone marrow of ...

Graft-versus-host disease (GVHD) is a common and severe complication that occurs after stem cell transplantation, where the ...

Australian biotech Mesoblast can go ahead with a US filing for its off-the-shelf stem cell therapy for acute graft-versus-host disease (GVHD), after negotiations with the FDA. The ‘rolling ...

Chronic graft-vs.-host disease (cGVHD) can be debilitating for people who have had an allogeneic stem cell transplant. In GVHD, the transplanted donor cells recognize the recipient’s tissues as ...